Objectives: IQ motif containing GTPase-activating protein 1 (IQGAP1) acts as a scaffold for aberrant mitogen-activated protein kinase (MAPK) signaling driven by KRAS mutations in pancreatic ductal adenocarcinoma (PDAC). We determined the role of IQGAP1 in clonogenic growth and metastasis in PDAC.
T he prognosis of patients diagnosed with pancreatic ductal adenocarcinoma (PDAC) is poor, with 5-year survival rates of less than 10%. 1 Surgery is potentially curative in early-stage disease, but most patients experience local or metastatic recurrence following resection. Therefore, treatments that inhibit tumor relapse and dissemination may improve clinical outcomes. Tumor regrowth requires long-term maintenance of clonogenic growth, and in many normal and malignant tissues, the signaling pathways regulating self-renewal are distinct from those involved in cell proliferation and survival. Although many factors affecting PDAC cell proliferation have been identified, the processes regulating self-renewal are not fully understood.
Mutations in members of the RAS family of small GTPase proteins are found in a wide range of human cancers, and KRAS mutations are present in greater than 90% of PDAC cases. 2 
KRAS
mutations are thought to be initiating events in PDAC as they are found in pancreatic intraepithelial neoplasia lesions that are carcinoma precursors and can induce PDAC in genetically engineered mouse models. 3, 4 In leukemia, multiple myeloma, and skin cancers, RAS mutations can lead to aberrant self-renewal, [5] [6] [7] but their impact in PDAC is unclear. KRAS mutations activate downstream pathways including mitogen-activated protein kinase (MAPK) signaling to promote cell proliferation and survival. 8 MEK inhibitors block MAPK signaling and are clinically effective in BRAFmutant melanoma. [9] [10] [11] However, resistance to MEK inhibition is common, 12 and targeting downstream pathway components, such as ERK1/2, may be more efficacious.
Mitogen-activated protein kinase signaling requires intracellular scaffold proteins, including IQ motif containing GTPaseactivating protein 1 (IQGAP1), to bring RAF, MEK, and ERK1/2 into close proximity. 13 The WW domain of IQGAP1 consists of amino acids 643-744 and specifically binds to ERK1/2.
14 The loss of IQGAP1 can inhibit MAPK signaling by preventing the interaction of ERK1/2 with other MAPK pathway components.
14 Furthermore, peptides mimicking the WW domain of IQGAP1 can sequester ERK1/2 to distally inhibit the MAPK pathway and slow the growth of PDAC in mutant KRAS mouse models. 15 We studied IQGAP1 in PDAC and found that down-regulation of its expression inhibited the clonogenic growth and invasion of KRAS-dependent PDAC in vitro as well as tumor initiation and metastasis in vivo. In addition, treatment with a peptide mimicking the IQGAP1 WW domain (WW peptide) inhibited tumor colony formation and growth. Therefore, MAPK signaling mediates clonogenic PDAC growth, and treatment with the WW peptide can disrupt IQGAP1 function and represents a novel approach to this disease.
MATERIALS AND METHODS

Cell Lines and Xenografts
Capan-1 and PANC-1 PDAC cells were maintained in Dulbecco modified eagle medium (DMEM) supplemented with 10% fetal bovine serum, penicillin, streptomycin, and L-glutamine. Low-passage patient-derived xenografts (PDXs) generated from primary surgical specimens and the single-cell dissociation of PDXs have been previously described. 16, 17 Lentivirus Production and Transduction Lentiviral particles containing an inducible shRNA vector containing IQGAP1 targeting sequences (5′-GCCCACAT TGTGCCTTTATTTCTC-3′, control 5′-CCTAAGGTTAAGT CGCCCTCGCTC-3′) or a scrambled control sequence cloned into the pLKO.Tet.On shRNA lentivector (Addgene, Cambridge, Mass) were generated as previously described. 6 Transduced PDAC cells were selected with 2 μg/mL puromycin, and shRNAs were induced with 25 ng/mL (Capan-1) or 100 ng/mL (PANC-1) doxycycline (Sigma, St Louis, Mo) for 3 or 7 days.
Colony Formation
Colony formation in methylcellulose was performed as previously described. 16, 17 Prior to plating, control and IQGAP1-directed shRNA were induced with doxycycline for 3 days or cells were treated with 1 μM scrambled control or WW peptide for 7 days. 15 Peptide treatments were carried out on days 1 and 4. For secondary plating, colonies were digested with trypsin, washed, and replated in methylcellulose.
Transwell Migration
Following treatment with doxycycline or peptides as above, cells were seeded in tissue culture inserts with 8.0 μm pores (Corning, Corning, NY) in DMEM and placed in wells containing DMEM supplemented with 10% fetal bovine serum for 24 hours. Membranes were fixed with the ProLong Gold Antifade Reagent with DAPI (Thermo Fisher, Waltham, Mass), and cells were counted using a fluorescence microscope (Nikon Instruments, Melville, NY).
Animal Studies
All mouse experiments were approved by the Johns Hopkins University Animal Care and Use Committee. To calculate tumorinitiating cell (TIC) frequency, control or IQGAP1 shRNA Capan-1 cells (1 Â 10 6 ) were injected subcutaneously into NOD-scid IL2Rgamma null (NSG) mice and allowed to form palpable tumors. Animals were treated for 7 days with water containing 2 mg/mL doxycycline, then tumors were harvested, dissociated into single cells, and injected into naive secondary recipients (10 3 -10 5 cells). After 5 weeks, TIC frequency was calculated using extreme limiting dilution analysis. 18 For evaluation of metastatic potential, Capan-1 control or IQGAP1 shRNA cells (2.5 Â 10 5 ) were orthotopically injected into the pancreas of NSG mice. After 14 days, 1 mouse from each group was killed to macroscopically confirm primary tumor formation, and the remaining 4 mice were treated with water containing 2 mg/mL doxycycline for 25 days.
Mice were killed, and metastases were identified by necropsy and hematoxylin-eosin-stained histological analysis. For WW peptide treatment, athymic nude mice were injected subcutaneously with Capan-1 cells or low-passage PDAC PDXs, and following the development of palpable tumors, mice were treated with 50 mg/kg scrambled control or WW peptide by intraperitoneal injection twice a day for 21 days. Tumors were measured twice a week, and tumor volume was calculated using the formula V = (L Â W 2 )/2.
Quantitative Reverse Transcriptase-Polymerase Chain Reaction Analysis mRNA was purified using the RNeasy Mini kit (Qiagen, Germantown, Md), and cDNA was synthesized using SuperScript III First Strand Synthesis System (Thermo Fisher). Relative mRNA expression was determined using Taqman probes (IQGAP1 probe #: hs00896595_m1, GAPDH probe #: hs99999905_m1) (Thermo Fisher) and normalized to GAPDH expression.
Western Blot Analysis
Protein was extracted using Mammalian Protein Extraction Reagent (Thermo Fisher) with protease and phosphatase inhibitors and electrophoresed on NuPage Novex 4-12% Bis-Tris Protein Gels, transferred to polyvinylidene fluoride membranes, and blocked for 1 hour with 5% wt/vol bovine serum albumin or 5% nonfat milk in 1Â Tris-buffered saline and 0.1% Tween-20. Immunoblots were performed using rabbit anti-IQGAP1 (Abcam ab86064; Abcam, Cambridge, Mass), anti-pERK1/2 (Cell Signaling CST9101S; Cell Signaling, Danvers, Mass), anti-ERK1/2 (Cell Signaling CST9102) polyclonal, and mouse anti-GAPDH monoclonal (Abcam ab8245) antibodies. Proteins were detected using the Amersham ECL reagent (GE Healthcare Life Sciences, Pittsburgh, Pa) on HyBlot CL film (Denville Scientific, Holliston, Mass). Densitometric analysis of protein expression was performed using ImageLab software (BioRad, Hercules, Calif ). 
Flow Cytometry
Aldehyde dehydrogenase (ALDH) staining was carried out using the Aldefluor reagent (Stemcell Technologies, Cambridge, Mass) according to the manufacturer's protocol. Aldehyde dehydrogenase-positive cells were identified by generating a control gate based on cells stained with Aldefluor in the presence of the ALDH inhibitor diethylaminobenzaldehyde. Analysis was performed using FlowJo software 8.7 (BD Biosciences, Franklin Lake, NJ).
Data Analysis
Statistical differences were analyzed using 2-tailed, unpaired Student t test with Welch correction in GraphPad Prism 6 software (La Jolla, Calif ) for Mac OS. P < 0.05 was considered significant.
RESULTS
IQGAP1 Is Required for In Vitro PDAC Clonogenic Growth and Self-renewal
Local relapse and metastatic relapse are dependent on the maintenance of long-term clonogenic growth potential, and activating mutations in RAS family members can induce aberrant self-renewal in multiple systems, including multiple myeloma and epithelial cells. 6, 19, 20 IQGAP1 facilitates MAPK signaling downstream of KRAS, and to determine its role in PDAC, we generated stable cell lines with doxycycline-inducible shRNA constructs (Supplemental Fig. 1A , http://links.lww.com/MPA/ A694). As expected, the loss of IQGAP1 expression was associated with the inhibition of MAPK signaling in Capan-1 and PANC-1 PDAC cells as evidenced by decreased levels of pERK after 3 and 7 days of doxycycline exposure (Fig. 1A) . We examined clonogenic growth and found that IQGAP1 knockdown significantly inhibited Capan-1 tumor cell colony formation by approximately 50% compared with cells with a scrambled control shRNA construct (Fig. 1B , P < 0.001). This inhibition was not due to the induction of cell death, as the number of viable cells did not significantly change following IQGAP1 knockdown (Supplemental Fig. 1B , http://links.lww.com/MPA/A694). In addition, the loss of IQGAP1 expression significantly inhibited self-renewal as the loss of clonogenic growth was maintained during serial colony formation despite the lack of further treatment with doxycycline ( Fig. 1B , P < 0.05). We also examined the impact of IQGAP1 knockdown on PANC-1 cells that are not dependent on mutant KRAS for cell proliferation or survival 21 and found that primary and secondary colony formation was increased, rather than decreased as in KRAS-dependent Capan-1 cells, compared with cells with control shRNA (Supplementary Fig. 1C , http://links.lww. com/MPA/A694). In many diseases, self-renewal is enriched in rare populations of cancer stem cells (CSCs), 22 and in PDAC, we previously demonstrated that CSCs express higher levels of ALDH. 23 We quantified PDAC CSCs and found that IQGAP1 knockdown did not significantly change the frequency of Capan-1 or PANC-1 ALDH + cells ( Supplementary Fig. 1D , http://links. lww.com/MPA/A694). Therefore, IQGAP1-mediated MAPK signaling impacts clonogenic growth and self-renewal in KRASdependent, but not independent, PDAC cells without significantly changing the frequency of phenotypically defined CSCs.
Loss of IQGAP1 Decreases In Vivo TIC Frequency
We examined the impact of IQGAP1 on PDAC tumor initiation in vivo and injected immunodeficient NSG mice with IQGAP1 or control shRNA Capan-1 cells to form subcutaneous tumors ( Supplementary Fig. 2A , http://links.lww.com/MPA/A694). We then treated mice with doxycycline for 7 days, harvested tumors, verified IQGAP1 knockdown, and injected tumor cells in limiting dilution into naive recipients (Supplementary Figs. 2A , B, http:// links.lww.com/MPA/A694). Although tumor volumes did not significantly differ between the groups at the end of the 7-day treatment period (data not shown), the TIC frequency significantly decreased from approximately 1 in 300 to 1 in 18,000 in control and IQGAP1 shRNA cells, respectively (Table 1 and Supplemental Fig. 2A , http://links.lww.com/MPA/A694, P < 0.001). Therefore, IQGAP1 impacts the tumor-initiating potential of PDAC.
Loss of IQGAP1 Decreases Cell Migration and Metastasis
The development of metastatic disease requires cell invasion and migration in addition to clonogenic growth. We examined cell migration in vitro and found that these properties were significantly inhibited in Capan-1, but not PANC-1, cells following IQGAP1 knockdown compared with cells with the control shRNA ( Fig. 2A , P < 0.05). To assess the role of IQGAP1 in metastasis, we orthotopically injected IQGAP1 or control shRNA Capan-1 cells into the pancreas of NSG mice and allowed primary tumors to form (Fig. 2B) . Following 25 days of doxycycline treatment, primary tumors were identified in all mice (Figs. 2C, D) . Liver metastases were identified in all mice injected with control shRNA cells, and additional metastases were present in the spleen (75%), intestine (25%), and mesentery (25%) of animals. In contrast, liver metastases were limited to 25% and splenic lesions to 50% of the animals receiving IQGAP1 shRNA cells. Therefore, IQGAP1 impacts PDAC cell migration in vitro and metastasis in vivo.
WW Peptide Inhibits Clonogenic Growth and Migration
A peptide mimicking the WW domain of IQGAP1 can disrupt IQGAP1-ERK interactions and extend the survival of PDAC mouse models. 15 To determine whether the WW peptide could limit PDAC clonogenic growth, we treated Capan-1 cells with the WW peptide and found that it inhibited ERK activation, tumor colony formation, and cell migration compared with a scrambled sequence control peptide (Figs. 3A, B and Supplementary Fig. 3A , http://links.lww.com/MPA/A694). In vivo WW peptide treatment significantly decreased the growth of subcutaneous Capan-1 tumors and 1 of 2 PDXs (Figs. 3C, D , and Supplementary Fig. 3B , http://links.lww.com/MPA/A694). Therefore, the WW peptide inhibits clonogenic growth in PDAC and may represent a novel treatment strategy.
DISCUSSION
The poor prognosis of PDAC patients is driven by high rates of tumor relapse and metastatic dissemination. Self-renewal maintains clonogenic growth over time and is required for both local tumor regrowth and the formation of metastatic lesions at distal sites. Mutant KRAS signaling has been shown to impact selfrenewal and metastasis in several solid tumors, 19, 20, 24 and IQGAP1 is overexpressed in CD133 + glioblastoma TICs. 25 Here we demonstrate that mutant KRAS-dependent PDAC is dependent on IQGAP1 for clonogenic growth, self-renewal, tumor initiation, and metastasis.
Our data also suggest that the effects of IQGAP1 knockdown are due to the disruption of MAPK signaling, similar to other studies. 6, 15 Recently, the interaction between the IQGAP1 and ERK2 has been found to be mediated by the IQ, rather than WW, domains. 26 Although the loss of total IQGAP1 expression would not distinguish between these possibilities, we found that the WW peptide decreased ERK phosphorylation and clonogenic growth, suggesting that the WW domain is important in PDAC. However, it is possible that the effects of IQGAP1 loss in PDAC are mediated by its scaffold function for an alternative pathway, such as the interaction between Cdc42 and Rac1, 27 or another functional property.
Cancer stem cells have been identified in many diseases and are enriched for tumor-initiating and self-renewal potential. In solid tumors, CSCs have also been associated with metastatic disease. 23, [28] [29] [30] [31] Despite the inhibition of clonogenic growth and self-renewal, we did not detect a change in the frequency of ALDH + PDAC CSCs following the knockdown of IQGAP1. It is possible that the loss of IQGAP1 expression impacts both CSCs and non-CSCs equally so that the TIC frequency remains relatively constant. It is also possible that IQGAP1 knockdown uncouples the functional features of CSCs from their phenotype or that the changes we observed are attributable to ALDH-negative TICs.
The identification of molecular targets to inhibit aberrant self-renewal has been limited in most diseases, but blocking several potential pathways, such as developmental signaling pathways, may impact normal stem cells. Because KRAS mutations are typically limited to cancer cells, targeting aberrant RAS signaling may improve relapse rates and the development of metastatic disease without inhibiting normal tissue homeostasis. Similar to previous studies, 6 ,15 the administration of the WW peptide did not appear to impact the health of mice, suggesting that this approach may be cancer specific.
